Ed Arce
Stock Analyst at WestPark Capital
(4.00)
# 580
Out of 4,981 analysts
470
Total ratings
45.94%
Success rate
13.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Initiates: Buy | $24 | $8.30 | +189.16% | 12 | Sep 2, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $23.47 | +27.82% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.70 | +1,624.39% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $3.87 | +1,837.98% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $17.32 | +246.42% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.95 | +154.24% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.61 | +131.73% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $5.37 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.94 | +538.30% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $10.20 | +586.27% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $21.80 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.31 | +5,468.45% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.59 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.76 | +373.37% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $65.62 | -46.66% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $43.48 | +72.51% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $8.07 | +160.22% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $74.31 | -3.11% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $432.27 | -6.31% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.61 | -16.79% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $30.31 | +213.43% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.30 | +202.33% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.46 | +12.11% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $24.19 | +98.43% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $7.23 | +3.81% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.68 | +632.60% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $12.75 | +2.00% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.59 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $23.77 | +5.17% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.51 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.94 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $24.81 | -71.79% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $37.33 | -43.74% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.14 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 2, 2025
Initiates: Buy
Price Target: $24
Current: $8.30
Upside: +189.16%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $23.47
Upside: +27.82%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.70
Upside: +1,624.39%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $3.87
Upside: +1,837.98%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $17.32
Upside: +246.42%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.95
Upside: +154.24%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.61
Upside: +131.73%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.37
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.94
Upside: +538.30%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $10.20
Upside: +586.27%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $21.80
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.31
Upside: +5,468.45%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.76
Upside: +373.37%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $65.62
Upside: -46.66%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $43.48
Upside: +72.51%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $8.07
Upside: +160.22%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $74.31
Upside: -3.11%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $432.27
Upside: -6.31%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.61
Upside: -16.79%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $30.31
Upside: +213.43%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.30
Upside: +202.33%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.46
Upside: +12.11%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $24.19
Upside: +98.43%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $7.23
Upside: +3.81%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.68
Upside: +632.60%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $12.75
Upside: +2.00%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $23.77
Upside: +5.17%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.51
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.94
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $24.81
Upside: -71.79%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $37.33
Upside: -43.74%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.14
Upside: -